Latest Conference Coverage


CMSC Live: 2025 Annual Meeting Day 2

CMSC Live: 2025 Annual Meeting Day 2

May 30th 2025

Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.


Bryan Walker, MHS, PA-C  (Credit: LinkedIn)

Survey Results Point to High Rates of Burnout Among APPs and Pharmacists in Neurology

May 29th 2025

A new survey presented at CMSC 2025 highlighted the prevalence of burnout and job-related stress among neurology-based advanced practice providers and clinical pharmacists in the United States.


Rebound Effect Not Observed With Multiple Sclerosis Therapy Ozanimod

Rebound Effect Not Observed With Multiple Sclerosis Therapy Ozanimod

May 29th 2025

New findings reveal ozanimod shows no significant rebound effect in relapsing MS patients after treatment discontinuation, ensuring safer transitions.


Single-Center Study Provides Support for Natalizumab Use in Pregnant Women With Multiple Sclerosis

Single-Center Study Provides Support for Natalizumab Use in Pregnant Women With Multiple Sclerosis

May 29th 2025

Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.


CMSC Poster Gives Demographic Insights for Phase 3 PERSEUS Study of Tolebrutinib

CMSC Poster Gives Demographic Insights for Phase 3 PERSEUS Study of Tolebrutinib

May 29th 2025

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.


Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population

Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population

May 28th 2025

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.


NeuroVoices: Elisabeth Sonesson, PhD, on Imlifidase’s Targeted, Fast-Acting Approach to GBS

NeuroVoices: Elisabeth Sonesson, PhD, on Imlifidase’s Targeted, Fast-Acting Approach to GBS

May 28th 2025

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.


Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

May 27th 2025

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]


Abstracts for the 2025 CMSC Annual Meeting Are Now Live!

Abstracts for the 2025 CMSC Annual Meeting Are Now Live!

May 27th 2025

The 39th CMSC Annual Meeting is set to be held May 28-31, 2025, in Phoenix, Arizona. The International Journal of MS Care has published the abstracts.


Early Data Support Continued Development of NVG-2089 as IVIg Alternative in CIDP

Early Data Support Continued Development of NVG-2089 as IVIg Alternative in CIDP

May 27th 2025

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.


Phase 4 Trial to Test Transition From IVIg to Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy

Phase 4 Trial to Test Transition From IVIg to Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy

May 24th 2025

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.


Rituximab’s Effect on NfL Levels Points to Possible Therapeutic Advantage in CIDP

Rituximab’s Effect on NfL Levels Points to Possible Therapeutic Advantage in CIDP

May 23rd 2025

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.


Jong Wook Chang, PhD  (Credit: Sungkyunkwan University)

Preclinical Study Suggests Stem Cell Therapy EN001 and Insulin May Improve Symptoms of Charcot-Marie-Tooth Disease Type 1A

May 23rd 2025

Researchers reported that both EN001 and insulin improved muscle strength and nerve function in models of Charcot-Marie-Tooth disease type 1A, with combined treatment showing enhanced effects.


Márcia Waddington-Cruz, MD, PhD  (Credit: Radcliffe Cardiology)

Eplontersen Exceeds Established Thresholds for Symptom and Disability Improvement in ATTRv-PN

May 22nd 2025

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.


ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

May 22nd 2025

New findings confirm vutrisiran's long-term safety and efficacy in treating hereditary transthyretin amyloidosis, enhancing patient quality of life.


Mechanism and Rationale Behind Imlifidase for Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

Mechanism and Rationale Behind Imlifidase for Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

May 22nd 2025

The vice president and franchise lead of Autoimmune at Hansa Biopharma discussed the rapid, antibody-cleaving mechanism of imlifidase and its potential to address unmet needs in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]


Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy

Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy

May 22nd 2025

Gene therapy arsa-cel significantly improves nerve function in children with late-infantile metachromatic leukodystrophy, outperforming traditional treatments.


Rajiv Mallick, PhD  (Credit: LinkedIn)

Real-World Study Highlights Reduced Disability Progression of CIDP With Immunoglobulin Therapy

May 21st 2025

A recent matched cohort analysis revealed that patients with CIDP treated with immunoglobulin had lower rates of assistive device deterioration and opioid use compared with those untreated.


ANX005 Outperforms IVIg and Plasma Exchange in Improving Guillain-Barré Syndrome Outcomes

ANX005 Outperforms IVIg and Plasma Exchange in Improving Guillain-Barré Syndrome Outcomes

May 21st 2025

Matched analysis from the IGOS dataset showed ANX005-treated patients had greater improvements in GBS disability scores over time compared with those receiving IVIg or plasma exchange.


Outlining Phase 3 VITALIZE and MOBILIZE Trials of Riliprubart in CIDP: Luis Querol, MD, PhD

Outlining Phase 3 VITALIZE and MOBILIZE Trials of Riliprubart in CIDP: Luis Querol, MD, PhD

May 21st 2025

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, outlined the goals and significance of the VITALIZE and MOBILIZE phase 3 trials evaluating riliprubart in standard-of-care and treatment-refractory CIDP populations. [WATCH TIME: 3 minutes]


NeuroVoices: Brad Kamitaki, MD, on Aiming to Improve Dementia Care in Asian and Pacific American Communities

NeuroVoices: Brad Kamitaki, MD, on Aiming to Improve Dementia Care in Asian and Pacific American Communities

May 21st 2025

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.


Riliprubart Demonstrates Maintained Efficacy, Safety in Subgroup Analyses of CIDP

Riliprubart Demonstrates Maintained Efficacy, Safety in Subgroup Analyses of CIDP

May 20th 2025

Subgroup data from a phase 2 CIDP trial showed riliprubart maintained consistent efficacy and safety across patient demographics, disease characteristics, and prior treatment exposures.


Roser Velasco, MD, PhD  (Credit: IDIBELL)

Sarcopenia Shows Association to Higher Risk of Chemotherapy-Induced Peripheral Neurotoxicity

May 20th 2025

A newly presented study showed that patients with sarcopenia before starting chemotherapy had a greater likelihood of developing moderate to severe peripheral neurotoxicity.


Biomarker and Subgroup Insights on Novel CIDP Therapy Riliprubart: Luis Querol, MD, PhD

Biomarker and Subgroup Insights on Novel CIDP Therapy Riliprubart: Luis Querol, MD, PhD

May 20th 2025

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, provided clinical context on sustained responses and new biomarker findings from exploratory phase 2 data on riliprubart in CIDP. [WATCH TIME: 4 minutes]


Eplontersen Slows Disability Progression and Deterioration of Gait Speed in ATTRv Polyneuropathy

Eplontersen Slows Disability Progression and Deterioration of Gait Speed in ATTRv Polyneuropathy

May 20th 2025

Eplontersen showed promise in halting disability progression and improving gait speed in patients with hereditary amyloid polyneuropathy, according to recent study findings.


Sami Khella, MD  (Credit: The College of Physicians of Philadelphia)

UK Analysis Shows Low Transthyretin Levels Linked to Increased Risk of Multiple Diseases

May 19th 2025

A recently presented biobank data analysis showed associations between reduced transthyretin and higher incidence of conditions such as Alzheimer disease, cardiovascular disease, and rheumatoid arthritis.


Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms

Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms

May 19th 2025

Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.


David Cornblath, MD  (Credit: ResearchGate)

Efficacy of CIDP Treatments Immunoglobulin 10% and Efgartigimod Compared Through Matching-Adjusted Indirect Analysis

May 19th 2025

A recently presented matching-adjusted indirect comparison assessed outcomes of immune globulin subcutaneous (Human)-ifas, 10% solution versus subcutaneous efgartigimod in patients with CIDP.


A More Selective Immune Approach to CIDP With Riliprubart: Claudia Sommer, MD

A More Selective Immune Approach to CIDP With Riliprubart: Claudia Sommer, MD

May 19th 2025

The president-elect of the Peripheral Nerve Society provided clinical context the mechanism and clinical relevance of riliprubart, a targeted complement inhibitor in development for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 3 minutes]

© 2025 MJH Life Sciences

All rights reserved.